InterventionsReview

Cardiovascular Outcomes of Oral Semaglutide in High Risk Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

AHA Scientific Sessions 2025 Abstract

The paper

Akhter HAR, Malik HK, Sivasubramanian D et al.

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4367751

doi.org/10.1161/circ.152.suppl_3.4367751

Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026